BioAge Labs, Inc. Securities Fraud Class Action Lawsuit: What You Need to Know
On February 12, 2025, Glancy Prongay & Murray LLP announced that investors who have suffered losses on their BioAge Labs, Inc. (“BioAge” or the “Company”) investments have the opportunity to lead the securities fraud class action lawsuit against the company. The lawsuit alleges that BioAge and certain of its executives violated securities laws by making false and misleading statements regarding the Company’s business, operations, and financial condition.
Background on BioAge Labs, Inc.
BioAge is a biotechnology company focused on developing and commercializing therapies to extend human healthspan. The Company’s lead product candidate, BIO-01, is a senolytic drug designed to eliminate senescent cells, which are believed to contribute to aging and various age-related diseases. In November 2023, BioAge announced positive results from a Phase 2a clinical trial of BIO-01, which sent the Company’s stock price soaring.
The Alleged False Statements
However, according to the securities fraud class action lawsuit, the Company and its executives made false and misleading statements about the clinical trial results and the progress of the development of BIO-01. Specifically, the lawsuit alleges that the Company downplayed the risks associated with the drug and overstated its potential benefits. It also alleges that the Company failed to disclose material information about the trial design and data.
The Impact on Investors
As a result of these alleged false statements, BioAge’s stock price was artificially inflated, causing investors to suffer significant losses when the truth was revealed. If you purchased BioAge securities between November 1, 2023 and January 31, 2025, you may be eligible to participate in the securities fraud class action lawsuit against the Company.
The Impact on the Biotech Industry
The BioAge securities fraud class action lawsuit is a reminder of the importance of transparency and accuracy in the biotech industry. The lawsuit could lead to increased scrutiny of clinical trial data and disclosures, as well as increased legal and regulatory risks for biotech companies. It may also impact investor confidence in the sector and lead to increased volatility in biotech stock prices.
Next Steps
If you believe you have suffered losses as a result of investing in BioAge Labs, Inc. securities, you may be eligible to participate in the securities fraud class action lawsuit against the Company. To learn more and to potentially serve as a lead plaintiff, click here before March 10, 2025 (lead plaintiff deadline).
It is important to note that past performance is not indicative of future results. This information is not legal advice and should not be relied upon as such. Consult with a securities attorney for specific advice regarding your situation.
Conclusion
The securities fraud class action lawsuit against BioAge Labs, Inc. highlights the importance of accurate and transparent disclosures in the biotech industry. If you suffered losses as a result of investing in BioAge securities, you may be eligible to participate in the class action lawsuit. For more information, contact Glancy Prongay & Murray LLP before the lead plaintiff deadline.
- BioAge Labs, Inc. is a biotech company focused on developing therapies to extend human healthspan.
- The Company’s lead product candidate, BIO-01, is a senolytic drug designed to eliminate senescent cells.
- In November 2023, BioAge announced positive results from a Phase 2a clinical trial of BIO-01, which caused the stock price to soar.
- The securities fraud class action lawsuit alleges that BioAge and certain executives made false and misleading statements about the clinical trial results and the progress of BIO-01 development.
- The lawsuit could lead to increased scrutiny of clinical trial data and disclosures, as well as increased legal and regulatory risks for biotech companies.
- If you suffered losses as a result of investing in BioAge securities, you may be eligible to participate in the securities fraud class action lawsuit against the Company.
